 Biocept, Inc. has reported a strong rise in full-year 2021 revenue due to growth in volumes for reverse transcription RT PCR coronavirus COVID-19 testing. The company, a leading provider of molecular diagnostic assays, products and services, said net revenues for the year to December 31, 2021, reached 61.2 million, a 123 increase from 27.5 million in 2020. 